Levetiracetam Dosing for Intracranial Hemorrhage
For seizure prophylaxis in adults with acute intracranial hemorrhage, the evidence does not support routine use of levetiracetam, but if used, administer 500-1000 mg IV every 12 hours for a maximum of 7 days.
Key Recommendation Based on Most Recent Evidence
The 2025 Neurocritical Care Society guidelines specifically addressing nontraumatic intracerebral hemorrhage recommend avoiding prophylactic antiseizure medications entirely 1. This represents the most current, high-quality guideline evidence directly addressing your question. The guideline found that prophylactic ASM use was associated with increased adverse events and higher risk of poor functional outcomes at 90 days, with no significant reduction in early or late seizures.
When Levetiracetam Is Used Despite Guidelines
If clinicians choose to use seizure prophylaxis despite the guideline recommendation against it, the dosing should be:
Loading Dose
- 1000-1500 mg IV over 15 minutes 2
- Higher loading doses (≥40 mg/kg) are associated with increased intubation rates without improved seizure control 3
Maintenance Dosing
Standard dosing (500 mg IV every 12 hours) is frequently subtherapeutic in critically ill patients. Recent pharmacokinetic data demonstrates that neurocritically ill patients eliminate levetiracetam rapidly, with clearance rates of 5.3 L/h and elimination half-life of only 4.8 hours 4.
Optimal maintenance regimens based on 2024 evidence:
The 2024 prospective study showed that patients receiving >1000 mg total daily dose achieved target serum levels (12-46 μg/mL) in 64% of cases versus only 45% with standard 500 mg twice daily dosing 5. Higher dosing reduced seizure odds by 68% (adjusted OR 0.32, p=0.018).
Duration
Maximum 7 days 1. The 2025 NCS guideline specifically recommends short duration (≤7 days) if prophylaxis is used, as longer durations showed no additional benefit and increased quality-adjusted life-year losses.
Clinical Context and Caveats
The fundamental issue is whether to use prophylaxis at all. The 2025 meta-analysis of 15 studies encompassing patients with nontraumatic ICH found no benefit for seizure prevention but demonstrated harm through increased adverse events and worse functional outcomes 1.
Exceptions where prophylaxis may be considered:
- Lobar hemorrhage location (higher seizure risk)
- Cortical involvement
- Large hemorrhage volume
- History of prior seizures (though this becomes treatment, not prophylaxis)
For traumatic brain injury specifically: The 2026 severity-stratified cohort study of 51,000 patients found levetiracetam reduced early epilepsy only in severe TBI (GCS 3-8), with no long-term protection in any severity group 6. This supports limiting prophylaxis to severe TBI cases only.
Renal Dosing Adjustments
For patients with renal impairment, adjust maintenance doses per FDA labeling 2:
- CrCl 50-80: 500-1000 mg every 12 hours
- CrCl 30-50: 250-750 mg every 12 hours
- CrCl <30: 250-500 mg every 12 hours
- Dialysis: 500-1000 mg every 24 hours with 250-500 mg supplemental dose post-dialysis
Adverse Effects to Monitor
Levetiracetam carries significant psychiatric and cognitive risks that are particularly relevant in brain-injured patients:
- Behavioral changes, aggression, irritability (13% in adults) 2
- Memory impairment and cognitive dysfunction 7, 6
- Metabolic disturbances 6
- Consider alternative agents (e.g., oxcarbazepine) in patients with pre-existing psychiatric illness 8
Status Epilepticus Context
The question asks about "head bleed" which could imply active seizures rather than prophylaxis. If the patient is actively seizing, this becomes treatment of status epilepticus, not prophylaxis:
For benzodiazepine-refractory status epilepticus, the 2024 ACEP guidelines recommend levetiracetam as a second-line agent with similar efficacy to fosphenytoin or valproate 9. In this acute seizure context, use 30-60 mg/kg IV loading dose (maximum 4500 mg) 10.